Abstract
A single dose of 200 mg/kg razoxane protected mice against the subchronic lethal effects (i.e. within 21 days) of 10 mg/kg daunomycin. When the razoxane dose was split into 2 doses of 100 mg/kg, even better protection against higher doses of daunomycin was obtained. The best protective effect was seen when the razoxane was given 24 h before or simultaneously with the daunomycin, and it was still present, though less, 24 h later. Histopathological examination to determine the site of protection showed it to be in the small bowel. Marrow and cardiac tissue showed no evident changes when examined by light microscopy.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Herman E. H., Mhatre R. M., Chadwick D. P. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943). Toxicol Appl Pharmacol. 1974 Mar;27(3):517–526. doi: 10.1016/0041-008x(74)90031-3. [DOI] [PubMed] [Google Scholar]
- Millar J. L., Hudspith B. N., McElwain T. J., Phelps T. A. Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer. 1978 Jul;38(1):137–142. doi: 10.1038/bjc.1978.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Woodman R. J., Cysyk R. L., Kline I., Gang M., Venditti J. M. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother Rep. 1975 Jul-Aug;59(4):689–695. [PubMed] [Google Scholar]
- Yap H. Y., Benjamin R. S., Blumenschein G. R., Hortobagyi G. N., Tashima C. K., Buzdar A. U., Bodey G. P. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan;63(1):77–83. [PubMed] [Google Scholar]